Match tier Institution-verified
Presence Current · Arkansas
Last published 2026
Sources Institutional record
Refreshed 2026-08-20

Hong-yu Li

Sourced from institutional research profiles (UAMS TRI or ARA).

◆ ARA Academy Federal Grant PI

Medicinal Chemistry

UAMS

Also affiliated: The University of Texas at San Antonio Health Science Center (2026)

Graduate Student Researcher

1 pubs

Research Areas

Biomedical Subjects

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • fms-Like Tyrosine Kinase 3
  • Dose-Response Relationship, Drug
  • Drug Screening Assays, Antitumor
  • Humans
  • Structure-Activity Relationship
  • Molecular Structure
  • Leukemia, Myeloid, Acute
  • Apoptosis
  • Cell Line, Tumor
  • Cell Proliferation

Links

Lab Website

Edit your profile

OverviewAI-generated summary

Hong-yu Li investigates the development of novel therapeutic agents, with a current focus on the identification and characterization of potent inhibitors for cancer cells. His research has explored the mechanism of action of a compound against MV4-11 cells, extending beyond its known inhibition of FLT3. This work aims to uncover pathways that contribute to cellular response and potential therapeutic efficacy.

Li serves as the Principal Investigator on a grant from the NIH/National Cancer Institute, funded at $1, for the "Drug Development of Skp2 PROTACs in Cancer." This project involves the development of targeted protein degraders, known as PROTACs, to address cancer by specifically degrading key cellular proteins involved in cancer progression. Li is also an ARA Academy member, designated as an ARA Scholar, and has co-authored one publication with collaborator Xiuqi Wang from the University of Arkansas for Medical Sciences.

Metrics

  • Publications: 1

Selected Publications

  • An unprecedented potent inhibitor of MV4-11 cells: investigations into the mechanism of action beyond FLT3 inhibition (2026)
    Bioorganic Chemistry DOI OpenAlex

View all publications on OpenAlex →

ARA Academy 2016 ARA Scholar

Federal Grants 1 $1 total

NIH Contact PI May 2023 - Jul 2023

Drug Development of Skp2 PROTACs in Cancer

National Cancer Institute $1 R01

Collaboration Network

4 Collaborators 2 Institutions 1 Country

Top Collaborators

View profile →

Similar Researchers

Based on overlapping research topics

Amal Shoeib University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology Receptor Mechanisms and Signaling Structure-Activity Relationship
Good match 5 shared topics
Maha Hanafi University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology Receptor Mechanisms and Signaling Structure-Activity Relationship
Good match 4 shared topics
Ahmed D. Iqbal Arkansas State University
Cancer Treatment and Pharmacology Structure-Activity Relationship Pharmacological Effects and Toxicity Studies
Good match 4 shared topics
Marlee Martin University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology Pharmacological Effects and Toxicity Studies Drug Transport and Resistance Mechanisms
Good match 3 shared topics
Han M University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology Pharmacological Effects and Toxicity Studies Drug Transport and Resistance Mechanisms
Good match 3 shared topics
Tsigereda Weldemichael University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology Acute Myeloid Leukemia Research Pharmacological Effects and Toxicity Studies
Good match 3 shared topics